Home / Business and Economy / Roivant Shares Surge on Mid-Stage Trial Success
Roivant Shares Surge on Mid-Stage Trial Success
8 Sep
Summary
- Experimental drug targets high blood pressure linked to lung disease.
- Mid-stage study met its primary treatment goals successfully.
- Roivant's shares jumped approximately 20% in premarket trading.
An experimental drug developed by Roivant has demonstrated success in a mid-stage clinical trial. The study focused on patients experiencing high blood pressure that is linked to a particular type of lung disease.
The trial met its main objectives, signaling positive progress for the drug's development. In response to this news, Roivant's stock price saw a notable increase of approximately 20% in premarket trading on Tuesday.
This advancement is part of Roivant's ongoing strategy to broaden its late-stage drug pipeline. The company recently secured U.S. approval for Lisraya, a treatment designed for skin and muscle diseases.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
